• Mashup Score: 0

    Since February 1, 1980, the identical standardized Greenville Gastric Bypass has been performed in 397 morbidly obese patients with an operative mortality rate of 0.8%. The operation effectively controlled weight and maintained satisfactory weight loss even after 6 years (mean weights and ranges: Pr …

    Tweet Tweets with this article
    • The first paper by Walter Pories discussed the findings of the Greenville Gastric Bypass and how it could remit type 2 diabetes - #T2DM #DM #diabetes #obesity #bariatricsurgery 5/ The control of diabetes mellitus withe the Greenville Gastric Bypass - https://t.co/YWjY406B9z

  • Mashup Score: 2

    About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…

    Tweet Tweets with this article
    • What to do with #LMPCI IN #DM. Is pendulum swinging? Editorial w/ @timir_paul @CRMjournal @GreggWStone @ajaykirtane @SVRaoMD @ameeshisath @ABaliMD @HenrytTimothy @WestchesterMed https://t.co/dVLpRlRJVr

    • What to do with #LMPCI IN #DM. Is pendulum swinging? Editorial w/ ⁦@timir_paul⁩ ⁦@CRMjournal⁩ ⁦@GreggWStone⁩ ⁦@ajaykirtane⁩ ⁦@SVRaoMD⁩ ⁦@ameeshisath⁩ ⁦@ABaliMD⁩ ⁦@HenrytTimothy⁩ ⁦⁦@WestchesterMed⁩ https://t.co/dVLpRm8MXr

  • Mashup Score: 0

    The proven cardiovascular benefits of these agents can’t be realized unless prices drop by as much as 90%, researchers say.

    Tweet Tweets with this article
    • Sky-high Cost of #SGLT2i and #GLP1-RA Deter 1st-line Use The proven CV benefits of these agents can’t be realized unless prices drop by as much as 90% #HeartFailure #DM @TCTMD @mmamas1973 @ShelleyZieroth @dr_benoy_n_shah @DrMarthaGulati @DLBHATTMD https://t.co/ut9UixUMub

  • Mashup Score: 1

    AbstractAims. Randomized controlled trials have demonstrated the efficacy of mineralocorticoid receptor (MR) antagonism in delaying chronic kidney disease (CKD)

    Tweet Tweets with this article
    • #Aldosterone in CKD and renal outcomes These observational data suggest that pathogenic #aldosteronism may play a role in CKD progression #MRA therapy as a method to delay CKD progression in those without #DM ? https://t.co/eQsr7Np7Gn #EHJ #HeartFailure @ESC_Journals https://t.co/KW4FjhyLpC